BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58:388-396. [PMID: 23258593 DOI: 10.1002/hep.26208] [Cited by in Crossref: 207] [Cited by in F6Publishing: 165] [Article Influence: 25.9] [Reference Citation Analysis]
Number Citing Articles
1 Ashby K, Zhuang W, González-Jimenez A, Alvarez-Alvarez I, Lucena MI, Andrade RJ, Aithal GP, Suzuki A, Chen M. Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. J Hepatol 2021;75:333-41. [PMID: 33845060 DOI: 10.1016/j.jhep.2021.03.021] [Reference Citation Analysis]
2 Miller ED, Abu-sbeih H, Chalasani NP. Drug-Induced Liver Injury in Older Adults. In: Pitchumoni CS, Dharmarajan T, editors. Geriatric Gastroenterology. Cham: Springer International Publishing; 2019. pp. 1-16. [DOI: 10.1007/978-3-319-90761-1_53-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Raschi E, De Ponti F. Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. World J Hepatol. 2015;7:1761-1771. [PMID: 26167249 DOI: 10.4254/wjh.v7.i13.1761] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
4 Yang F, Liang Y, Xu L, Ji L, Yao N, Liu R, Shi L, Liang T. Exploration in the cascade working mechanisms of liver injury induced by total saponins extracted from Rhizoma Dioscorea bulbifera. Biomedicine & Pharmacotherapy 2016;83:1048-56. [DOI: 10.1016/j.biopha.2016.08.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
5 Shah F, Leung L, Barton HA, Will Y, Rodrigues AD, Greene N, Aleo MD. Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays. Toxicol Sci 2015;147:500-14. [DOI: 10.1093/toxsci/kfv152] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 12.5] [Reference Citation Analysis]
6 Stephens C, Andrade RJ, Lucena MI. Mechanisms of drug-induced liver injury. Curr Opin Allergy Clin Immunol. 2014;14:286-292. [PMID: 24915546 DOI: 10.1097/aci.0000000000000070] [Cited by in Crossref: 68] [Cited by in F6Publishing: 17] [Article Influence: 11.3] [Reference Citation Analysis]
7 Zhang L, Niu M, Wei AW, Tang JF, Tu C, Bai ZF, Zou ZS, Xiao XH, Liu YP, Wang JB. Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum. Arch Toxicol 2020;94:245-56. [PMID: 31630224 DOI: 10.1007/s00204-019-02595-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
8 Brown AC. Liver toxicity related to herbs and dietary supplements: Online table of case reports. Part 2 of 5 series. Food Chem Toxicol 2017;107:472-501. [PMID: 27402097 DOI: 10.1016/j.fct.2016.07.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
9 Thakkar S, Li T, Liu Z, Wu L, Roberts R, Tong W. Drug-induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity. Drug Discov Today 2020;25:201-8. [PMID: 31669330 DOI: 10.1016/j.drudis.2019.09.022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
10 Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146:914-928. [PMID: 24389305 DOI: 10.1053/j.gastro.2013.12.032] [Cited by in Crossref: 147] [Cited by in F6Publishing: 118] [Article Influence: 18.4] [Reference Citation Analysis]
11 Ivanov S, Semin M, Lagunin A, Filimonov D, Poroikov V. In Silico Identification of Proteins Associated with Drug-induced Liver Injury Based on the Prediction of Drug-target Interactions. Mol Inform 2017;36. [PMID: 28145637 DOI: 10.1002/minf.201600142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Schleiff MA, Payakachat S, Schleiff BM, Swamidass SJ, Boysen G, Miller GP. Impacts of diphenylamine NSAID halogenation on bioactivation risks. Toxicology 2021;458:152832. [PMID: 34107285 DOI: 10.1016/j.tox.2021.152832] [Reference Citation Analysis]
13 Fernandes GFDS, Man Chin C, Dos Santos JL. Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds. Pharmaceuticals (Basel) 2017;10:E51. [PMID: 28587160 DOI: 10.3390/ph10020051] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
14 Alempijevic T, Zec S, Milosavljevic T. Drug-induced liver injury: Do we know everything? World J Hepatol. 2017;9:491-502. [PMID: 28443154 DOI: 10.4254/wjh.v9.i10.491] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
15 Villanueva-Paz M, Morán L, López-Alcántara N, Freixo C, Andrade RJ, Lucena MI, Cubero FJ. Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. Antioxidants (Basel) 2021;10:390. [PMID: 33807700 DOI: 10.3390/antiox10030390] [Reference Citation Analysis]
16 Thakkar S, Chen M, Fang H, Liu Z, Roberts R, Tong W. The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury. Expert Rev Gastroenterol Hepatol 2018;12:31-8. [PMID: 28931315 DOI: 10.1080/17474124.2018.1383154] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
17 Scarim CB, Jornada DH, Chelucci RC, de Almeida L, Dos Santos JL, Chung MC. Current advances in drug discovery for Chagas disease. Eur J Med Chem 2018;155:824-38. [PMID: 30033393 DOI: 10.1016/j.ejmech.2018.06.040] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 14.7] [Reference Citation Analysis]
18 Teschke R, Danan G. Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease. Drug Saf. 2016;39:729-744. [PMID: 27091053 DOI: 10.1007/s40264-016-0423-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
19 Busche M, Tomilova O, Schütte J, Werner S, Beer M, Groll N, Hagmeyer B, Pawlak M, Jones PD, Schmees C, Becker H, Schnabel J, Gall K, Hemmler R, Matz-soja M, Damm G, Beuck S, Klaassen T, Moer J, Ullrich A, Runge D, Schenke-layland K, Gebhardt R, Stelzle M. HepaChip-MP – a twenty-four chamber microplate for a continuously perfused liver coculture model. Lab Chip 2020;20:2911-26. [DOI: 10.1039/d0lc00357c] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Maiuri AR, Wassink B, Turkus JD, Breier AB, Lansdell T, Kaur G, Hession SL, Ganey PE, Roth RA. Synergistic Cytotoxicity from Drugs and Cytokines In Vitro as an Approach to Classify Drugs According to Their Potential to Cause Idiosyncratic Hepatotoxicity: A Proof-of-Concept Study. J Pharmacol Exp Ther 2017;362:459-73. [PMID: 28687704 DOI: 10.1124/jpet.117.242354] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
21 Chan R, Benet LZ. Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of In Vitro Methodologies vs BDDCS Classification. Toxicol Res (Camb) 2018;7:358-70. [PMID: 29785262 DOI: 10.1039/C8TX00016F] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
22 Lu RJ, Zhang Y, Tang FL, Zheng ZW, Fan ZD, Zhu SM, Qian XF, Liu NN. Clinical characteristics of drug-induced liver injury and related risk factors. Exp Ther Med. 2016;12:2606-2616. [PMID: 27703513 DOI: 10.3892/etm.2016.3627] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
23 Xu Y, Dai Z, Chen F, Gao S, Pei J, Lai L. Deep Learning for Drug-Induced Liver Injury. J Chem Inf Model 2015;55:2085-93. [PMID: 26437739 DOI: 10.1021/acs.jcim.5b00238] [Cited by in Crossref: 157] [Cited by in F6Publishing: 117] [Article Influence: 26.2] [Reference Citation Analysis]
24 European Association for the Study of the Liver;  Clinical Practice Guideline Panel: Chair;  Panel members;  EASL Governing Board representative. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70:1222-1261. [PMID: 30926241 DOI: 10.1016/j.jhep.2019.02.014] [Cited by in Crossref: 198] [Cited by in F6Publishing: 132] [Article Influence: 99.0] [Reference Citation Analysis]
25 Scarim CB, Jornada DH, Machado MGM, Ferreira CMR, Dos Santos JL, Chung MC. Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. Eur J Med Chem 2019;162:378-95. [PMID: 30453246 DOI: 10.1016/j.ejmech.2018.11.013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
26 Thompson RA, Isin EM, Ogese MO, Mettetal JT, Williams DP. Reactive Metabolites: Current and Emerging Risk and Hazard Assessments. Chem Res Toxicol 2016;29:505-33. [DOI: 10.1021/acs.chemrestox.5b00410] [Cited by in Crossref: 79] [Cited by in F6Publishing: 58] [Article Influence: 15.8] [Reference Citation Analysis]
27 Zhang J, Ren L, Yang X, White M, Greenhaw J, Harris T, Wu Q, Bryant M, Papoian T, Mattes W, Shi Q. Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett 2018;291:138-48. [PMID: 29655783 DOI: 10.1016/j.toxlet.2018.04.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
28 Zhu J, Seo JE, Wang S, Ashby K, Ballard R, Yu D, Ning B, Agarwal R, Borlak J, Tong W, Chen M. The Development of a Database for Herbal and Dietary Supplement Induced Liver Toxicity. Int J Mol Sci 2018;19:E2955. [PMID: 30274144 DOI: 10.3390/ijms19102955] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
29 Hadziyannis SJ, Vassilopoulos D, Sevastianos V, Hadziyannis E. Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B? Curr Hepatology Rep 2014;13:256-63. [DOI: 10.1007/s11901-014-0236-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
30 McGill MR, Jaeschke H. Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation. Expert Rev Mol Diagn 2018;18:797-807. [PMID: 30080986 DOI: 10.1080/14737159.2018.1508998] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
31 Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol. 2015;63:503-514. [PMID: 25912521 DOI: 10.1016/j.jhep.2015.04.016] [Cited by in Crossref: 200] [Cited by in F6Publishing: 159] [Article Influence: 33.3] [Reference Citation Analysis]
32 Aleo MD, Shah F, He K, Bonin PD, Rodrigues AD. Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol 2017;30:1219-29. [PMID: 28437613 DOI: 10.1021/acs.chemrestox.7b00048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
33 Melchart D, Hager S, Albrecht S, Dai J, Weidenhammer W, Teschke R. Herbal Traditional Chinese Medicine and suspected liver injury: A prospective study. World J Hepatol 2017;9:1141-57. [PMID: 29085558 DOI: 10.4254/wjh.v9.i29.1141] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
34 Forsch K, Schöning V, Assmann GM, Moser C, Siewert B, Butterweck V, Drewe J. In vitro hepatotoxicity of Petasites hybridus extract (Ze 339) depends on the concentration, the cytochrome activity of the cell system, and the species used. Phytother Res 2020;34:184-92. [PMID: 31631423 DOI: 10.1002/ptr.6516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Raschi E, De Ponti F. Drug-induced liver injury: Towards early prediction and risk stratification. World J Hepatol 2017;9:30-7. [PMID: 28105256 DOI: 10.4254/wjh.v9.i1.30] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
36 Zgheib NK, Branch RA. Drug metabolism and liver disease: a drug-gene-environment interaction. Drug Metab Rev 2017;49:35-55. [PMID: 27957864 DOI: 10.1080/03602532.2016.1271807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
37 Yu K, Geng X, Chen M, Zhang J, Wang B, Ilic K, Tong W. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos. 2014;42:744-750. [PMID: 24464804 DOI: 10.1124/dmd.113.056267] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 8.4] [Reference Citation Analysis]
38 Norman BH. Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies. J Med Chem 2020;63:11397-419. [PMID: 32511920 DOI: 10.1021/acs.jmedchem.0c00524] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
39 Chan R, Benet LZ. Evaluation of DILI Predictive Hypotheses in Early Drug Development. Chem Res Toxicol 2017;30:1017-29. [PMID: 28257576 DOI: 10.1021/acs.chemrestox.7b00025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
40 Thomas AM, Lewis JH. Nonacetaminophen Drug-Induced Acute Liver Failure. Clinics in Liver Disease 2018;22:301-24. [DOI: 10.1016/j.cld.2018.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
41 Choi PJ, Sutherland HS, Tong AST, Blaser A, Franzblau SG, Cooper CB, Lotlikar MU, Upton AM, Guillemont J, Motte M, Queguiner L, Andries K, Van den Broeck W, Denny WA, Palmer BD. Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units. Bioorg Med Chem Lett 2017;27:5190-6. [PMID: 29107541 DOI: 10.1016/j.bmcl.2017.10.042] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
42 Teschke R, Danan G. Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue? Expert Opin Drug Metab Toxicol. 2017;13:425-438. [PMID: 27822971 DOI: 10.1080/17425255.2017.1252749] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
43 Barton P, Riley RJ. A new paradigm for navigating compound property related drug attrition. Drug Discov Today 2016;21:72-81. [PMID: 26404453 DOI: 10.1016/j.drudis.2015.09.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
44 Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J. Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization. Bioorganic & Medicinal Chemistry 2018;26:5099-117. [DOI: 10.1016/j.bmc.2018.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
45 Mosedale M, Watkins PB. Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury. J Med Chem 2020;63:6436-61. [PMID: 32037821 DOI: 10.1021/acs.jmedchem.9b01297] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]
46 Vall A, Sabnis Y, Shi J, Class R, Hochreiter S, Klambauer G. The Promise of AI for DILI Prediction. Front Artif Intell 2021;4:638410. [PMID: 33937745 DOI: 10.3389/frai.2021.638410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Liu L, Fu L, Zhang JW, Wei H, Ye WL, Deng ZK, Zhang L, Cheng Y, Ouyang D, Cao Q, Cao DS. Three-Level Hepatotoxicity Prediction System Based on Adverse Hepatic Effects. Mol Pharm 2019;16:393-408. [PMID: 30475633 DOI: 10.1021/acs.molpharmaceut.8b01048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
48 Raschi E, De Ponti F. Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. Front Pharmacol 2019;10:1235. [PMID: 31708776 DOI: 10.3389/fphar.2019.01235] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
49 Williams DP, Lazic SE, Foster AJ, Semenova E, Morgan P. Predicting Drug-Induced Liver Injury with Bayesian Machine Learning. Chem Res Toxicol 2020;33:239-48. [PMID: 31535850 DOI: 10.1021/acs.chemrestox.9b00264] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
50 Shimizu Y, Sasaki T, Takeshita JI, Watanabe M, Shizu R, Hosaka T, Yoshinari K. Identification of average molecular weight (AMW) as a useful chemical descriptor to discriminate liver injury-inducing drugs. PLoS One 2021;16:e0253855. [PMID: 34170966 DOI: 10.1371/journal.pone.0253855] [Reference Citation Analysis]
51 Mishra P, Chen M. Direct-Acting Antivirals for Chronic Hepatitis C: Can Drug Properties Signal Potential for Liver Injury?Gastroenterology. 2017;152:1270-1274. [PMID: 28327365 DOI: 10.1053/j.gastro.2017.03.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
52 Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014;89:95-106. [PMID: 24388027 DOI: 10.1016/j.mayocp.2013.09.016] [Cited by in Crossref: 208] [Cited by in F6Publishing: 167] [Article Influence: 29.7] [Reference Citation Analysis]
53 Wu L, Liu Z, Auerbach S, Huang R, Chen M, McEuen K, Xu J, Fang H, Tong W. Integrating Drug's Mode of Action into Quantitative Structure-Activity Relationships for Improved Prediction of Drug-Induced Liver Injury. J Chem Inf Model 2017;57:1000-6. [PMID: 28350954 DOI: 10.1021/acs.jcim.6b00719] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
54 Ancuceanu R, Hovanet MV, Anghel AI, Furtunescu F, Neagu M, Constantin C, Dinu M. Computational Models Using Multiple Machine Learning Algorithms for Predicting Drug Hepatotoxicity with the DILIrank Dataset. Int J Mol Sci 2020;21:E2114. [PMID: 32204453 DOI: 10.3390/ijms21062114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
55 Schadt HS, Wolf A, Pognan F, Chibout SD, Merz M, Kullak-Ublick GA. Bile acids in drug induced liver injury: Key players and surrogate markers. Clin Res Hepatol Gastroenterol 2016;40:257-66. [PMID: 26874804 DOI: 10.1016/j.clinre.2015.12.017] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 9.2] [Reference Citation Analysis]
56 Hunt CM, Yuen NA, Stirnadel-Farrant HA, Suzuki A. Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database. Regul Toxicol Pharmacol. 2014;70:519-526. [PMID: 25236535 DOI: 10.1016/j.yrtph.2014.09.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
57 Wu L, Huang R, Tetko IV, Xia Z, Xu J, Tong W. Trade-off Predictivity and Explainability for Machine-Learning Powered Predictive Toxicology: An in-Depth Investigation with Tox21 Data Sets. Chem Res Toxicol 2021;34:541-9. [PMID: 33513003 DOI: 10.1021/acs.chemrestox.0c00373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
58 Mazzolari A, Vistoli G, Testa B, Pedretti A. Prediction of the Formation of Reactive Metabolites by A Novel Classifier Approach Based on Enrichment Factor Optimization (EFO) as Implemented in the VEGA Program. Molecules 2018;23:E2955. [PMID: 30428514 DOI: 10.3390/molecules23112955] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
59 Li Z, Fisher C, Gardner I, Ghosh A, Litchfield J, Maurer TS. Modeling Exposure to Understand and Predict Kidney Injury. Seminars in Nephrology 2019;39:176-89. [DOI: 10.1016/j.semnephrol.2018.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Broccatelli F, E.c.a Hop C, Wright M. Strategies to optimize drug half-life in lead candidate identification. Expert Opinion on Drug Discovery 2019;14:221-30. [DOI: 10.1080/17460441.2019.1569625] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
61 Ortega-Alonso A, Stephens C, Lucena MI, Andrade RJ. Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. Int J Mol Sci. 2016;17. [PMID: 27187363 DOI: 10.3390/ijms17050714] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 7.6] [Reference Citation Analysis]
62 Leeson PD. Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs. Chem Res Toxicol 2018;31:494-505. [PMID: 29722540 DOI: 10.1021/acs.chemrestox.8b00044] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
63 Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology. 2014;60:1015-1022. [PMID: 24799086 DOI: 10.1002/hep.27206] [Cited by in Crossref: 150] [Cited by in F6Publishing: 116] [Article Influence: 21.4] [Reference Citation Analysis]
64 Teschke R, Danan G. Drug induced liver injury with analysis of alternative causes as confounding variables. Br J Clin Pharmacol 2018;84:1467-77. [PMID: 29607530 DOI: 10.1111/bcp.13593] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
65 Lewis JH. Drug-induced liver injury, dosage, and drug disposition: is idiosyncrasy really unpredictable? Clin Gastroenterol Hepatol. 2014;12:1556-1561. [PMID: 24530601 DOI: 10.1016/j.cgh.2014.02.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
66 Chen M, Tung CW, Shi Q, Guo L, Shi L, Fang H, Borlak J, Tong W. A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' model. Arch Toxicol 2014;88:1439-49. [PMID: 24958025 DOI: 10.1007/s00204-014-1276-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
67 Moulin F, Flint O. In Vitro Models for the Prediction of Drug-Induced Liver Injury in Lead Discovery. In: Urbán L, Patel VF, Vaz RJ, editors. Antitargets and Drug Safety. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2015. pp. 125-58. [DOI: 10.1002/9783527673643.ch07] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
68 Hong H, Chen M, Ng HW, Tong W. QSAR Models at the US FDA/NCTR. Methods Mol Biol 2016;1425:431-59. [PMID: 27311476 DOI: 10.1007/978-1-4939-3609-0_18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
69 George N, Chen M, Yuen N, Hunt CM, Suzuki A. Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury. Regulatory Toxicology and Pharmacology 2018;94:101-7. [DOI: 10.1016/j.yrtph.2018.01.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
70 Björnsson ES. Liver Injury Associated with the Selective Progesterone Modulator Ulipristal. Drug Saf 2020;43:1201-4. [DOI: 10.1007/s40264-020-01004-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Baillie TA. Targeted Covalent Inhibitors for Drug Design. Angew Chem Int Ed 2016;55:13408-21. [DOI: 10.1002/anie.201601091] [Cited by in Crossref: 248] [Cited by in F6Publishing: 187] [Article Influence: 49.6] [Reference Citation Analysis]
72 He S, Zhang C, Zhou P, Zhang X, Ye T, Wang R, Sun G, Sun X. Herb-Induced Liver Injury: Phylogenetic Relationship, Structure-Toxicity Relationship, and Herb-Ingredient Network Analysis. Int J Mol Sci 2019;20:E3633. [PMID: 31349548 DOI: 10.3390/ijms20153633] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
73 Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci. 2015;17:14. [PMID: 26712744 DOI: 10.3390/ijms17010014] [Cited by in Crossref: 256] [Cited by in F6Publishing: 203] [Article Influence: 42.7] [Reference Citation Analysis]
74 Steger-hartmann T, Raschke M. Translating in vitro to in vivo and animal to human. Current Opinion in Toxicology 2020;23-24:6-10. [DOI: 10.1016/j.cotox.2020.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
75 He S, Ye T, Wang R, Zhang C, Zhang X, Sun G, Sun X. An In Silico Model for Predicting Drug-Induced Hepatotoxicity. Int J Mol Sci 2019;20:E1897. [PMID: 30999595 DOI: 10.3390/ijms20081897] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
76 Schadt S, Simon S, Kustermann S, Boess F, Mcginnis C, Brink A, Lieven R, Fowler S, Youdim K, Ullah M, Marschmann M, Zihlmann C, Siegrist Y, Cascais A, Di Lenarda E, Durr E, Schaub N, Ang X, Starke V, Singer T, Alvarez-sanchez R, Roth A, Schuler F, Funk C. Minimizing DILI risk in drug discovery — A screening tool for drug candidates. Toxicology in Vitro 2015;30:429-37. [DOI: 10.1016/j.tiv.2015.09.019] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
77 Syed SB, Arya H, Fu IH, Yeh TK, Periyasamy L, Hsieh HP, Coumar MS. Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer. Sci Rep 2017;7:7972. [PMID: 28801675 DOI: 10.1038/s41598-017-08062-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 13.3] [Reference Citation Analysis]
78 Samala N, Chalasani N. Drug-Induced Fatty Liver Disease. Curr Hepatology Rep 2018;17:260-9. [DOI: 10.1007/s11901-018-0418-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Kalgutkar AS. Designing around Structural Alerts in Drug Discovery. J Med Chem 2020;63:6276-302. [PMID: 31497963 DOI: 10.1021/acs.jmedchem.9b00917] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 12.5] [Reference Citation Analysis]
80 Björnsson ES. Drug-induced liver injury due to antibiotics. Scand J Gastroenterol 2017;52:617-23. [PMID: 28276834 DOI: 10.1080/00365521.2017.1291719] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
81 Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol 2014;6:601-12. [PMID: 25232453 DOI: 10.4254/wjh.v6.i8.601] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 6.4] [Reference Citation Analysis]
82 Umbaugh DS, Jaeschke H. Biomarkers of drug-induced liver injury: a mechanistic perspective through acetaminophen hepatotoxicity. Expert Rev Gastroenterol Hepatol 2021;15:363-75. [PMID: 33242385 DOI: 10.1080/17474124.2021.1857238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Vuppalanchi R, Gotur R, Reddy KR, Fontana RJ, Ghabril M, Kosinski AS, Gu J, Serrano J, Chalasani N. Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome.Clin Gastroenterol Hepatol. 2014;12:1550-1555. [PMID: 24362054 DOI: 10.1016/j.cgh.2013.12.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
84 Garcia-Cortes M, Robles-Diaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. Drug induced liver injury: an update.Arch Toxicol. 2020;94:3381-3407. [PMID: 32852569 DOI: 10.1007/s00204-020-02885-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
85 Effinger A, O'driscoll CM, Mcallister M, Fotaki N. Impact of gastrointestinal disease states on oral drug absorption – implications for formulation design – a PEARRL review. Journal of Pharmacy and Pharmacology 2019;71:674-98. [DOI: 10.1111/jphp.12928] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
86 Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, Devarbhavi H, Merz M, Lucena MI, Kaplowitz N, Aithal GP. Drug-induced liver injury. Nat Rev Dis Primers 2019;5:58. [PMID: 31439850 DOI: 10.1038/s41572-019-0105-0] [Cited by in Crossref: 81] [Cited by in F6Publishing: 59] [Article Influence: 40.5] [Reference Citation Analysis]
87 Pike KG, Barlaam B, Cadogan E, Campbell A, Chen Y, Colclough N, Davies NL, de-Almeida C, Degorce SL, Didelot M, Dishington A, Ducray R, Durant ST, Hassall LA, Holmes J, Hughes GD, Macfaul PA, Mulholland KR, Mcguire TM, Ouvry G, Pass M, Robb G, Stratton N, Wang Z, Wilson J, Zhai B, Zhao K, Al-huniti N. The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H -pyran-4-yl)-1,3-dihydro-2 H -imidazo[4,5- c ]quinolin-2-one). J Med Chem 2018;61:3823-41. [DOI: 10.1021/acs.jmedchem.7b01896] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 12.7] [Reference Citation Analysis]
88 Willyard C. Foretelling toxicity: FDA researchers work to predict risk of liver injury from drugs. Nat Med 2016;22:450-1. [PMID: 27149212 DOI: 10.1038/nm0516-450] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today. 2016;21:648-653. [PMID: 26948801 DOI: 10.1016/j.drudis.2016.02.015] [Cited by in Crossref: 115] [Cited by in F6Publishing: 82] [Article Influence: 23.0] [Reference Citation Analysis]
90 Sarges P, Steinberg JM, Lewis JH. Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature. Drug Saf 2016;39:801-21. [DOI: 10.1007/s40264-016-0427-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 9.4] [Reference Citation Analysis]
91 Cao L, Quan XB, Zeng WJ, Yang XO, Wang MJ. Mechanism of Hepatocyte Apoptosis. J Cell Death. 2016;9:19-29. [PMID: 28058033 DOI: 10.4137/jcd.s39824] [Cited by in Crossref: 42] [Cited by in F6Publishing: 20] [Article Influence: 8.4] [Reference Citation Analysis]
92 Dara L, Liu ZX, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2016;36:158-165. [PMID: 26484420 DOI: 10.1111/liv.12988] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 11.2] [Reference Citation Analysis]
93 Katarey D, Verma S. Drug-induced liver injury. Clin Med (Lond) 2016;16:s104-9. [PMID: 27956449 DOI: 10.7861/clinmedicine.16-6-s104] [Cited by in Crossref: 48] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
94 Rehman K, Munawar SM, Akash MSH, Buabeid MA, Chohan TA, Tariq M, Jabeen K, Arafa EA. Hesperidin improves insulin resistance via down-regulation of inflammatory responses: Biochemical analysis and in silico validation. PLoS One 2020;15:e0227637. [PMID: 31929574 DOI: 10.1371/journal.pone.0227637] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
95 Sebode M, Schulz L, Lohse AW. "Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis. Int J Mol Sci 2017;18:E1954. [PMID: 28895915 DOI: 10.3390/ijms18091954] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
96 Benesic A, Jalal K, Gerbes AL. Drug-Drug Combinations Can Enhance Toxicity as Shown by Monocyte-Derived Hepatocyte-like Cells From Patients With Idiosyncratic Drug-Induced Liver Injury. Toxicological Sciences 2019;171:296-302. [DOI: 10.1093/toxsci/kfz156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
97 Stephens C, Lucena MI, Andrade RJ. Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. In: Chen M, Will Y, editors. Drug-Induced Liver Toxicity. New York: Springer; 2018. pp. 477-96. [DOI: 10.1007/978-1-4939-7677-5_23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Huang S, Tung C, Fülöp F, Li J. Developing a QSAR model for hepatotoxicity screening of the active compounds in traditional Chinese medicines. Food and Chemical Toxicology 2015;78:71-7. [DOI: 10.1016/j.fct.2015.01.020] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
99 Mdluli K, Kaneko T, Upton A. Tuberculosis drug discovery and emerging targets. Ann N Y Acad Sci 2014;1323:56-75. [PMID: 24920100 DOI: 10.1111/nyas.12459] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
100 Weng Z, Wang K, Li H, Shi Q. A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications. Oncotarget 2015;6:17031-8. [PMID: 26220713 DOI: 10.18632/oncotarget.4400] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 7.4] [Reference Citation Analysis]
101 Proctor WR, Foster AJ, Vogt J, Summers C, Middleton B, Pilling MA, Shienson D, Kijanska M, Ströbel S, Kelm JM, Morgan P, Messner S, Williams D. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Arch Toxicol 2017;91:2849-63. [PMID: 28612260 DOI: 10.1007/s00204-017-2002-1] [Cited by in Crossref: 131] [Cited by in F6Publishing: 100] [Article Influence: 32.8] [Reference Citation Analysis]
102 Mdluli K, Kaneko T, Upton A. The tuberculosis drug discovery and development pipeline and emerging drug targets. Cold Spring Harb Perspect Med 2015;5:a021154. [PMID: 25635061 DOI: 10.1101/cshperspect.a021154] [Cited by in Crossref: 89] [Cited by in F6Publishing: 69] [Article Influence: 14.8] [Reference Citation Analysis]
103 Teschke R, Schulze J, Eickhoff A, Danan G. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment? Int J Mol Sci. 2017;18:E803. [PMID: 28398242 DOI: 10.3390/ijms18040803] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 9.5] [Reference Citation Analysis]
104 Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017;66:1154-64. [PMID: 28341748 DOI: 10.1136/gutjnl-2016-313369] [Cited by in Crossref: 196] [Cited by in F6Publishing: 149] [Article Influence: 49.0] [Reference Citation Analysis]
105 Teschke R, Danan G. Causality Assessment Methods in Drug-Induced Liver Injury. In: Chen M, Will Y, editors. Drug-Induced Liver Toxicity. New York: Springer; 2018. pp. 555-94. [DOI: 10.1007/978-1-4939-7677-5_27] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
106 Gerussi A, Natalini A, Antonangeli F, Mancuso C, Agostinetto E, Barisani D, Di Rosa F, Andrade R, Invernizzi P. Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. Int J Mol Sci 2021;22:4557. [PMID: 33925355 DOI: 10.3390/ijms22094557] [Reference Citation Analysis]
107 Wu Y, Zhu J, Fu P, Tong W, Hong H, Chen M. Machine Learning for Predicting Risk of Drug-Induced Autoimmune Diseases by Structural Alerts and Daily Dose. Int J Environ Res Public Health 2021;18:7139. [PMID: 34281077 DOI: 10.3390/ijerph18137139] [Reference Citation Analysis]
108 Li Y, Guo Z, Cui H, Wang T, Xu Y, Zhao J. Urantide prevents CCl4‑induced acute liver injury in rats by regulating the MAPK signalling pathway. Mol Med Rep 2021;24:688. [PMID: 34328202 DOI: 10.3892/mmr.2021.12329] [Reference Citation Analysis]
109 Carrascosa MF, Salcines-Caviedes JR, Lucena MI, Andrade RJ. Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity? J Hepatol 2015;62:751-2. [PMID: 25463547 DOI: 10.1016/j.jhep.2014.11.019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
110 Yamashita YI, Imai K, Mima K, Nakagawa S, Hashimoto D, Chikamoto A, Baba H. Idiosyncratic drug-induced liver injury: A short review. Hepatol Commun. 2017;1:494-500. [PMID: 29404475 DOI: 10.1002/hep4.1064] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
111 Ivashkin VT, Baranovsky AY, Raikhelson KL, Palgova LK, Maevskaya MV, Kondrashina EA, Marchenko NV, Nekrasova TP, Nikitin IG. Drug-Induced Liver Injuries (Clinical Guidelines for Physicians). Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2019;29:101-31. [DOI: 10.22416/1382-4376-2019-29-1-101-131] [Cited by in Crossref: 18] [Cited by in F6Publishing: 1] [Article Influence: 9.0] [Reference Citation Analysis]
112 Zhong T, Zhuang Z, Dong X, Wong KH, Wong WT, Wang J, He D, Liu S. Predicting Antituberculosis Drug-Induced Liver Injury Using an Interpretable Machine Learning Method: Model Development and Validation Study. JMIR Med Inform 2021;9:e29226. [PMID: 34283036 DOI: 10.2196/29226] [Reference Citation Analysis]
113 Zhu X, Xin Y, Chen Q. Chemical and in vitro biological information to predict mouse liver toxicity using recursive random forests. SAR and QSAR in Environmental Research 2016;27:559-72. [DOI: 10.1080/1062936x.2016.1201142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
114 Iorga A, Dara L, Kaplowitz N. Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis. Int J Mol Sci. 2017;18. [PMID: 28486401 DOI: 10.3390/ijms18051018] [Cited by in Crossref: 108] [Cited by in F6Publishing: 91] [Article Influence: 27.0] [Reference Citation Analysis]
115 Shah F, Bell IM. Cutaneous Adverse Events Caused by Sulfonamide-Containing Drugs: Reality or Perception? J Med Chem 2020;63:7447-57. [DOI: 10.1021/acs.jmedchem.9b01932] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
116 Minerali E, Foil DH, Zorn KM, Lane TR, Ekins S. Comparing Machine Learning Algorithms for Predicting Drug-Induced Liver Injury (DILI). Mol Pharm 2020;17:2628-37. [PMID: 32422053 DOI: 10.1021/acs.molpharmaceut.0c00326] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
117 Chalhoub WM, Sliman KD, Arumuganathan M, Lewis JH. Drug-induced liver injury: what was new in 2013? Expert Opin Drug Metab Toxicol. 2014;10:959-980. [PMID: 24746272 DOI: 10.1517/17425255.2014.909408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
118 Zhang J, Doshi U, Suzuki A, Chang C, Borlak J, Li AP, Tong W. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles. Chemico-Biological Interactions 2016;255:3-11. [DOI: 10.1016/j.cbi.2015.11.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
119 Björnsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int 2017;37:173-8. [DOI: 10.1111/liv.13308] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 9.6] [Reference Citation Analysis]
120 McEuen K, Borlak J, Tong W, Chen M. Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury.Int J Mol Sci. 2017;18. [PMID: 28640208 DOI: 10.3390/ijms18071335] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
121 Baillie TA. Zielgerichtete kovalente Inhibitoren für das Wirkstoffdesign. Angew Chem 2016;128:13606-19. [DOI: 10.1002/ange.201601091] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 6.2] [Reference Citation Analysis]
122 Funk C, Roth A. Current limitations and future opportunities for prediction of DILI from in vitro. Arch Toxicol 2017;91:131-42. [DOI: 10.1007/s00204-016-1874-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
123 Lewis JH. The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond. Clin Gastroenterol Hepatol. 2015;13:2173-2189.e8. [PMID: 26116527 DOI: 10.1016/j.cgh.2015.06.017] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
124 Danan G, Teschke R. Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch? Drug Saf. 2018;41:735-743. [PMID: 29502198 DOI: 10.1007/s40264-018-0654-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
125 Kaliyaperumal K, Grove JI, Delahay RM, Griffiths WJH, Duckworth A, Aithal GP. Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications.J Hepatol. 2018;69:948-957. [PMID: 29792895 DOI: 10.1016/j.jhep.2018.05.013] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
126 Teschke R, Larrey D, Melchart D, Danan G. Traditional Chinese Medicine (TCM) and herbal hepatotoxicity: RUCAM and the role of novel diagnostic biomarkers such as microRNAs. Medicines. 2016;3:18. [PMID: 28930128 DOI: 10.3390/medicines3030018] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
127 Lee SJ, Lee YJ, Park KK. The pathogenesis of drug-induced liver injury. Expert Rev Gastroenterol Hepatol 2016;10:1175-85. [PMID: 27248313 DOI: 10.1080/17474124.2016.1196133] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
128 Krasavin M, Lukin A, Bakholdina A, Zhurilo N, Onopchenko O, Borysko P, Zozulya S, Moore D, Tikhonova IG. Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR40) agonists. European Journal of Medicinal Chemistry 2017;140:229-38. [DOI: 10.1016/j.ejmech.2017.09.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
129 Chen M, Hong H, Fang H, Kelly R, Zhou G, Borlak J, Tong W. Quantitative Structure-Activity Relationship Models for Predicting Drug-Induced Liver Injury Based on FDA-Approved Drug Labeling Annotation and Using a Large Collection of Drugs. Toxicological Sciences 2013;136:242-9. [DOI: 10.1093/toxsci/kft189] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 7.6] [Reference Citation Analysis]
130 Liu S, Bu L, Zhang Y, Yan J, Li L, Li G, Song Z, Huang J. Subtle Structural Changes of Dyes Lead to Distinctly Different Fluorescent Behaviors in Cellular Context: The Role of G-Quadruplex DNA Interaction Using Coumarin-Quinazolinone Conjugates as a Case Study. Anal Chem 2021;93:5267-76. [PMID: 33724782 DOI: 10.1021/acs.analchem.1c00301] [Reference Citation Analysis]
131 Walker PA, Ryder S, Lavado A, Dilworth C, Riley RJ. The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development. Arch Toxicol 2020;94:2559-85. [PMID: 32372214 DOI: 10.1007/s00204-020-02763-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
132 Dara L, Kaplowitz N. Drug‐Induced Liver Injury. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 701-13. [DOI: 10.1002/9781119436812.ch54] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
133 Dixit VA. A simple model to solve a complex drug toxicity problem. Toxicol Res (Camb) 2019;8:157-71. [PMID: 30997019 DOI: 10.1039/c8tx00261d] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
134 Kumar S, Singh AP, Senapati S, Maiti P. Controlling Drug Delivery Using Nanosheet-Embedded Electrospun Fibers for Efficient Tumor Treatment. ACS Appl Bio Mater 2019;2:884-94. [DOI: 10.1021/acsabm.8b00735] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 9.5] [Reference Citation Analysis]
135 Ye JH, Ho YF, On AW, Chen WW, Huang YM, Huang WI, Tang YW. Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone. Int J Clin Pharm 2018;40:911-20. [PMID: 30051228 DOI: 10.1007/s11096-018-0698-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
136 Lewis JH. Causality assessment: which is best-expert opinion or RUCAM? Clinical Liver Dis. 2014;4:4-8. [PMID: 30992910 DOI: 10.1002/cld.365] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
137 Kawaguchi M, Nukaga T, Sekine S, Takemura A, Susukida T, Oeda S, Kodama A, Hirota M, Kouzuki H, Ito K. Mechanism-based integrated assay systems for the prediction of drug-induced liver injury. Toxicol Appl Pharmacol 2020;394:114958. [PMID: 32198022 DOI: 10.1016/j.taap.2020.114958] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
138 Frenzel C, Teschke R. Herbal Hepatotoxicity: Clinical Characteristics and Listing Compilation. Int J Mol Sci. 2016;17:pii: E588. [PMID: 27128912 DOI: 10.3390/ijms17050588] [Cited by in Crossref: 59] [Cited by in F6Publishing: 45] [Article Influence: 11.8] [Reference Citation Analysis]
139 Hammann F, Schöning V, Drewe J. Prediction of clinically relevant drug-induced liver injury from structure using machine learning: Prediction of DILI. J Appl Toxicol 2019;39:412-9. [DOI: 10.1002/jat.3741] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
140 Maurer TS, Smith D, Beaumont K, Di L. Dose Predictions for Drug Design. J Med Chem 2020;63:6423-35. [PMID: 31913040 DOI: 10.1021/acs.jmedchem.9b01365] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
141 Baudy AR, Otieno MA, Hewitt P, Gan J, Roth A, Keller D, Sura R, Van Vleet TR, Proctor WR. Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry. Lab Chip 2020;20:215-25. [DOI: 10.1039/c9lc00768g] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 31.0] [Reference Citation Analysis]
142 Chen M, Bisgin H, Tong L, Hong H, Fang H, Borlak J, Tong W. Toward predictive models for drug-induced liver injury in humans: are we there yet? Biomark Med. 2014;8:201-213. [PMID: 24521015 DOI: 10.2217/bmm.13.146] [Cited by in Crossref: 93] [Cited by in F6Publishing: 77] [Article Influence: 13.3] [Reference Citation Analysis]
143 Bayliss MK, Butler J, Feldman PL, Green DV, Leeson PD, Palovich MR, Taylor AJ. Quality guidelines for oral drug candidates: dose, solubility and lipophilicity. Drug Discovery Today 2016;21:1719-27. [DOI: 10.1016/j.drudis.2016.07.007] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 8.8] [Reference Citation Analysis]
144 Kalgutkar AS, Driscoll JP. Is there enough evidence to classify cycloalkyl amine substituents as structural alerts? Biochem Pharmacol 2020;174:113796. [PMID: 31926938 DOI: 10.1016/j.bcp.2020.113796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Raschi E, Poluzzi E, Koci A, Caraceni P, De Ponti F. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol. 2014;6:601-612. [PMID: 25232453 DOI: 10.4254/wjh.v6.i8.60] [Reference Citation Analysis]
146 Vincenzi B, Russo A, Terenzio A, Galvano A, Santini D, Vorini F, Antonelli-Incalzi R, Vespasiani-Gentilucci U, Tonini G. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol 2018;130:70-7. [PMID: 30196914 DOI: 10.1016/j.critrevonc.2018.06.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
147 Norman BH, Fisher MJ, Schiffler MA, Kuklish SL, Hughes NE, Czeskis BA, Cassidy KC, Abraham TL, Alberts JJ, Luffer-atlas D. Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury. J Med Chem 2018;61:2041-51. [DOI: 10.1021/acs.jmedchem.7b01806] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
148 Kaplowitz N. Avoiding idiosyncratic DILI: two is better than one. Hepatology 2013;58:15-7. [PMID: 23390057 DOI: 10.1002/hep.26295] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
149 Hong H, Thakkar S, Chen M, Tong W. Development of Decision Forest Models for Prediction of Drug-Induced Liver Injury in Humans Using A Large Set of FDA-approved Drugs. Sci Rep 2017;7:17311. [PMID: 29229971 DOI: 10.1038/s41598-017-17701-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
150 Teschke R, Danan G. Idiosyncratic Drug Induced Liver Injury, Cytochrome P450, Metabolic Risk Factors and Lipophilicity: Highlights and Controversies. Int J Mol Sci 2021;22:3441. [PMID: 33810530 DOI: 10.3390/ijms22073441] [Reference Citation Analysis]
151 Real M, Barnhill MS, Higley C, Rosenberg J, Lewis JH. Drug-Induced Liver Injury: Highlights of the Recent Literature. Drug Saf 2019;42:365-87. [PMID: 30343418 DOI: 10.1007/s40264-018-0743-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 36.0] [Reference Citation Analysis]
152 Jiang H, Jin Y, Yan H, Xu Z, Yang B, He Q, Luo P. Hepatotoxicity of FDA-approved small molecule kinase inhibitors. Expert Opin Drug Saf 2021;20:335-48. [PMID: 33356646 DOI: 10.1080/14740338.2021.1867104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Shinde Y, Ahmad I, Surana S, Patel H. The Mur Enzymes Chink in the Armour of Mycobacterium tuberculosis cell wall. Eur J Med Chem 2021;222:113568. [PMID: 34118719 DOI: 10.1016/j.ejmech.2021.113568] [Reference Citation Analysis]
154 Driscoll JP, Sadlowski CM, Shah NR, Feula A. Metabolism and Bioactivation: It's Time to Expect the Unexpected. J Med Chem 2020;63:6303-14. [PMID: 32267691 DOI: 10.1021/acs.jmedchem.0c00026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
155 Lewis JH, Gelderblom H, van de Sande M, Stacchiotti S, Healey JH, Tap WD, Wagner AJ, Pousa AL, Druta M, Lin CC, Baba HA, Choi Y, Wang Q, Shuster DE, Bauer S. Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. Oncologist 2021;26:e863-73. [PMID: 33289960 DOI: 10.1002/onco.13629] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
156 Haque T, Sasatomi E, Hayashi PH. Drug-Induced Liver Injury: Pattern Recognition and Future Directions. Gut Liver 2016;10:27-36. [PMID: 26696029 DOI: 10.5009/gnl15114] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
157 He C, Wan H. Drug metabolism and metabolite safety assessment in drug discovery and development. Expert Opinion on Drug Metabolism & Toxicology 2018;14:1071-85. [DOI: 10.1080/17425255.2018.1519546] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 11.7] [Reference Citation Analysis]
158 Sandhu N, Navarro V. Drug-Induced Liver Injury in GI Practice. Hepatol Commun. 2020;4:631-645. [PMID: 32363315 DOI: 10.1002/hep4.1503] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
159 Sistare FD, Mattes WB, Lecluyse EL. The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development. ILAR J 2017;57:186-211. [DOI: 10.1093/ilar/ilw025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
160 Tillmann HL, Barnhart HX, Serrano J, Rockey DC. Novel Approaches to Causality Adjudication in Drug-Induced Liver Disease. Curr Hepatol Rep 2018;17:276-82. [PMID: 30766772 DOI: 10.1007/s11901-018-0416-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
161 Chen M, Borlak J, Tong W. A Model to predict severity of drug-induced liver injury in humans. Hepatology. 2016;64:931-940. [PMID: 27302180 DOI: 10.1002/hep.28678] [Cited by in Crossref: 52] [Cited by in F6Publishing: 36] [Article Influence: 10.4] [Reference Citation Analysis]
162 Aleo MD, Shah F, Allen S, Barton HA, Costales C, Lazzaro S, Leung L, Nilson A, Obach RS, Rodrigues AD, Will Y. Moving beyond Binary Predictions of Human Drug-Induced Liver Injury (DILI) toward Contrasting Relative Risk Potential. Chem Res Toxicol 2020;33:223-38. [DOI: 10.1021/acs.chemrestox.9b00262] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
163 Mahmoud SY, Svensson F, Zoufir A, Módos D, Afzal AM, Bender A. Understanding Conditional Associations between ToxCast in Vitro Readouts and the Hepatotoxicity of Compounds Using Rule-Based Methods. Chem Res Toxicol 2020;33:137-53. [DOI: 10.1021/acs.chemrestox.8b00382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
164 Chen M, Borlak J, Tong W. Predicting idiosyncratic drug-induced liver injury - some recent advances. Expert Rev Gastroenterol Hepatol. 2014; May 23. [Epub ahead of print]. [PMID: 24857265 DOI: 10.1586/17474124.2014.922871] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
165 Chetty S, Ramesh M, Singh-Pillay A, Soliman ME. Recent advancements in the development of anti-tuberculosis drugs. Bioorg Med Chem Lett 2017;27:370-86. [PMID: 28017531 DOI: 10.1016/j.bmcl.2016.11.084] [Cited by in Crossref: 67] [Cited by in F6Publishing: 41] [Article Influence: 13.4] [Reference Citation Analysis]